EMV Capital Limited

**Qbot:** Q-Bot develops robots for the building and engineering industry, assisting human labour where there are significant cost or health and safety benefits. Their first application is in underfloor insulation for Victorian and early-20th century housing, leading to significant decreases in heat loss and improvements in comfort levels for residents. Winner of IEEE Invention and Entrepreneurship in Robotics and Automation Award at the 2015 IEEE/IFR Joint Forum on IERA Winner of Innovation Achievers Award (Highly Commended) at the 2015 CIOB International Innovation & Research Awards Nominated in the Energy Saving Product of the Year category at the 2015 CIBSE Building Performance Awards. **Sofant Technologies:** Developing a unique solution to steer the radio signal towards the receiver—improving range and performance of the antenna, whilst reducing the power required to operate the network, thereby avoiding the need for expensive cooling systems. Sofant’s patented smart antenna technology enables the steering of radio signals in future wireless systems in the 5G and SatCom space. **Vortex Biosciences:** A US-based oncology diagnostic company, developing a novel liquid biopsy automated instrument (VTX-1) and microfluidic cartridge for the isolation of circulating tumour cells from whole blood without the need for any pre-treatment. Vortex Biosciences’ main mission is to become the innovation leader in CTC capture technology delivering diagnostic tests that improve therapeutic decisions and save lives. The key potential is to revolutionise cancer diagnosis leading to better therapeutic outcomes. Its technology integrates cancer biology, microfluidic engineering, clinical research and the identification of cancer therapies and drug targets. **Wanda Health:** A remote monitoring healthcare analytics and management company for primary care patients with chronic diseases based in San Francisco. Wanda’s ambition is to significantly control and reduce hospitalisation rates through a Remote Monitoring System (RMS) that collects data from patients’ home to clinicians highlighting the high risks and allowing the action to prevent them. This life personalised medicine combined with secure computing and revolutionary data-mining and analytics improves the quality of life for people with chronic conditions, initially focused on congestive heart failure (CHF). Chronic disease in the US is accounted for 80% of the total health care bill representing a US$1.4 trillion expenditure. This could be significantly decreased through a severe chronic disease management and appropriate clinical measures.